Results 1 to 10 of about 16,883 (239)

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

New England Journal of Medicine, 2019
BACKGROUND Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF).
Willem Venter, Michelle A Moorhouse, Simiso Sokhela   +2 more
exaly   +2 more sources

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies

Viruses
In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults.
Mark Underwood, Rimgaile Urbaityte, Ruolan Wang, Joe Horton, James Oyee, Brian Wynne, Dainielle Fox, Bryn Jones, Choy Man, Jörg Sievers   +9 more
doaj   +2 more sources

Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study [PDF]

Journal of the International AIDS Society
Dolutegravir (DTG) is widely used for antiretroviral therapy (ART). We compared weight and blood pressure trends and examined the association between high blood pressure and weight gain among people living with HIV (PLHIV) switching to or starting DTG ...
Tinei Shamu, Matthias Egger, Tinashe Mudzviti, Cleophas Chimbetete, Justen Manasa, Nanina Anderegg   +5 more
openalex   +2 more sources

Dolutegravir use is related to lower HTLV-1 proviral load in people co-infected by HIV-1 [PDF]

Communications Medicine
Background Infection by human T-cell lymphotropic virus type 1 (HTLV-1) affects millions of people worldwide and causes severe diseases. To date, no specific treatment is available for HTLV infection. The purpose of this study was to determine the impact
Tatiana Fernandez, María B. Arriaga, Rafaela Mayoral, Eduardo M. Netto, Carlos Brites   +4 more
doaj   +2 more sources

Dolutegravir-associated hyperglycemia: a narrative review [PDF]

AIDS Research and Therapy
Dolutegravir is a preferred antiretroviral drug given its high resistance barrier and efficacy; however, reports from sub-Saharan Africa indicate increased hyperglycemia rates among individuals living with HIV on dolutegravir.
Allan Buzibye, Barbara Castelnuovo, Robert C. Bollinger, Joseph Ssebulime, Denis Omali, Daniel Muller, Frank Mulindwa, Eva Laker, Catriona Waitt, Irene Andia, Mohammed Lamorde, Ahmet Hoke, Bernard S. Bagaya, Yukari C. Manabe   +13 more
doaj   +2 more sources

Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South AfricaResearch in context

EClinicalMedicine, 2023
Summary: Background: The integrase strand transfer inhibitor (INSTI) dolutegravir is recommended in World Health Organization guidelines, but is associated with weight gain. We evaluated weight change in patients switching from efavirenz to dolutegravir
Alana T. Brennan, Cornelius Nattey, Emma M. Kileel, Sydney Rosen, Mhairi Maskew, Andrew C. Stokes, Matthew P. Fox, Willem D.F. Venter   +7 more
doaj   +2 more sources

Prevalence and Correlates of Hyperglycemia Among People Living With HIV and TB on Dolutegravir‐Based Antiretroviral Therapy in Zimbabwe: A Cross‐Sectional Study [PDF]

Health Science Reports
Background and Aims In low‐ and middle‐income countries, dolutegravir‐based antiretroviral therapy regimens are the preferred first‐line treatment for adults, adolescents, and children with human immunodeficiency virus (HIV).
Tafadzwa Zireva, Cuthbert Musarurwa, Arthur Mazhandu, Brenda Nherera, Shungu Munyati, Justen Manasa, Danai Tavonga Zhou, Donald Vhanda   +7 more
doaj   +2 more sources

A review of dolutegravir-associated weight gain and secondary metabolic comorbidities

SAGE Open Medicine
Dolutegravir is an integrase inhibitor and is recommended by the World Health Organization as the preferred first-line and second-line human immunodeficiency virus treatment in all populations.
Mohammed Jemal
doaj   +2 more sources

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Clinical Infectious Diseases, 2020
Background The 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) is indicated for treatment-naive adults with human immunodeficiency virus type 1 (HIV-1).
J. van Wyk, F. Ajana, F. Bisshop, S. De Wit, O. Osiyemi, J. Portilla Sogorb, J. Routy, C. Wyen, M. Ait‐Khaled, M. Nascimento, K. Pappa, Ruolan Wang, Jonathan Wright, A. Tenorio, B. Wynne, M. Aboud, M. Gartland, Kimberly Smith   +17 more
exaly   +2 more sources

Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women

CPT: Pharmacometrics & Systems Pharmacology
Optimal dosing in pregnant and lactating women requires an understanding of the pharmacokinetics in the mother, fetus, and breastfed infant. Physiologically‐based pharmacokinetic (PBPK) modeling can be used to simulate untested scenarios and hence ...
Jia Ning, Amita Pansari, Karen Rowland Yeo, Aki T. Heikkinen, Catriona Waitt, Lisa M. Almond   +5 more
doaj   +2 more sources